Get your free ETF data sample from our comprehensive offerings. Start your free trial→

Help us improve your experience. Please confirm your investor type:

Compare ETFs Easily

The Ultimate ETF Comparison Tool - Try Now!

Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.

›ETF Issuers›Franklin Templeton›HELX
HELX

Franklin Genomic Advancements ETF

Active ETFEquityTheme: BioTech & Genomics
Not rated

The HELX Exchange Traded Fund (ETF) is provided by Franklin Templeton. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.

Advertisement

Advertisement

$41.33
+$1.5 (+3.80%) yesterday
1:30 PM 08/07/26 Closed
1D price range
$41.02$41.41
52W price range
$27.67$41.32
YTD Perf.
+13.88%
YTD Flows
Annualized volatility
Fund AuM
€27M
Share class AuM
€27M
TTM Yield
Tracking Error
Tracking Difference
Characteristics
ISIN
US35473P5200
TER
0.5%
Inception date
2/25/2020
Issuer
Franklin Templeton
Dividend policy
Distributing
Compare similar ETFs
ETF Name1w perf.
HEAL
Global X Telemedicine & Digital Health ETF
+6.17%
FMED
Fidelity Disruptive Medicine ETF
+6.66%
EKG
First Trust Nasdaq Lux Digital Health Solutions ETF
+1.27%
ARKG
ARK Genomic Revolution ETF
+11.60%
GNOG
Global X Genomics & Biotechnology UCITS ETF
+7.07%
GNOM
Global X Genomics & Biotechnology ETF
+7.10%
WDNA
WisdomTree BioRevolution UCITS ETF
+2.02%
WDNA
WisdomTree BioRevolution Fund
+7.62%
PTH
Invesco DWA Healthcare Momentum ETF
+3.86%
AAKG
ARK Genomic Revolution UCITS ETF
+3.82%
GNMX
Corgi Genomics & Precision Medicine ETF
+6.80%
CURE
Global X S&P Biotech ETF
+1.42%
XBI
State Street SPDR S&P Biotech ETF
+7.02%
EDOC
Global X Telemedicine & Digital Health UCITS ETF
+4.28%
CURE
VanEck Genomics and Healthcare Innovators UCITS ETF
+5.94%
API
PerformanceDec 31, 2025 - Aug 7, 2026
-10%-5%0%5%10%JANMARMAYJUL
Flows
Join for free to unlock
Sector exposures
Data as of 06/30/26
Healthcare
96.75%
Non-Energy Materials
2.26%
Other
0.99%
Latest HELX news

No content available for this fund

FAQ about HELX

HELX is a Active ETF. This ETF provides exposure to Other Global Equities.
HELX carries a total expense ratio (TER) of 0.5%, indicating the annual cost for holding the fund.
HELX was introduced to the market on February 25, 2020. It trades on United States
Franklin Genomic Advancements ETF, HELX, is provided by Franklin Templeton. Learn more about Franklin Templeton here.
HELX oversees €27M in assets as of August 7, 2026.
HELX follows a distributing dividend policy, meaning it pays out income to investors.
As of June 30, 2026, HELX has significant geographic allocations in USA, United Kingdom and Republic of Korea.
As of June 30, 2026, HELX focuses largely on Healthcare and Non-Energy Materials.
As of June 30, 2026, HELX holds 61 positions in its portfolio, with 59.93% of assets concentrated in its top 15 holdings.
As of June 30, 2026, HELX top three holdings include Guardant Health, Inc., Natera, Inc. and Krystal Biotech, Inc..
The base currency of HELX is USD.
Top 10 holdings
Data as of 06/30/26
Guardant Health, Inc.
9.30%
Natera, Inc.
7.40%
Krystal Biotech, Inc.
6.51%
Ligand Pharmaceuticals, Inc.
4.56%
Adaptive Biotechnologies Corp.
4.01%
United Therapeutics Corp.
3.61%
BridgeBio Pharma, Inc.
3.39%
Eli Lilly & Co.
3.05%
Twist Bioscience Corp.
2.84%
Vertex Pharmaceuticals, Inc.
2.79%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
ETF TOOLS
ETF ScreenerCompare ETFsCompare ETF issuersWatchlistsETF Portfolio InsightsIndustry dataETF stock exposure finder
PLATFORM
Support and feedback
ETF NEWS & RESEARCH
Latest ETF NewsETF Research ReportsGlobal ETF Survey 2025Learn ETF investing
PROFESSIONAL SOLUTIONS
Enterprise SolutionsDue Diligence ServicesETF Data Services
SOLUTIONS FOR
Institutional investorsPrivate banksFinancial advisorsFintech and mediaIndividual investors
CONTACT US
General inquiries
Press and media
Advertising opportunities
Support and feedback
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Get our newsletters
Trackinsight